English
Rabbit anti Human Factor XIII-A
Rabbit anti Human Factor XIII-A, Polyclonal, Clone: Polyclonal
Artikelnummer
RAHu/FXIII-A
Verpackungseinheit
1 ml
Hersteller
Nordic-MUbio
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Clone: Polyclonal
Background: The defined antibody reactivity is restricted to Factor XIII and FXIIIa in plasma and to platelet FXIII. As tested at the level of sensitivity of immunoprecipitation techniques a single precipitin line is obtained in bidimensional electrophoresis, immunoelectrophoresis and double radial immunodiffusion (Ouchterlony) which shows a reaction of full identity with A subunits of FXIII. No reaction is obtained with FXIII-depleted plasma and with B subunits. In precipitating techniques as electroimmunodiffusion, immunoelectrophoresis and single and double radial immunodiffusion (Mancini, Ouchterlony). To prepare an adsorbent for immunoaffinity purification of FXIII. If used in more sensitive test procedures or as catching or detection antibody in solid phase immunoassays specificity controls should always be include. Increase in plasma FXIII has been observed in type IV hyperlipoproteinaemia and in combined hyperlipodaemia. Congenital and acquired FXIII deficiencies have also been reported. In some cases of myeloma, inhibition of FXIII activity by the paraproteins may occur.
Source: Plasma FXIII is an active transglutaminase until it is activated (FXIIIa). It consists of two A subunits joined as a dimer, connected to two B subunits (A2B2). Each A subunit has a molecular weight of 75,000 and each B subunit of 80,000, making an aggregate molecular weight of the whole molecule of 320,000. Normal plasma contains about 20mg/ml. Platelet FXIII consists of only A subunits synthesized in the megakaryocytes. It accounts for about 50% of the total blood FXIII activity with a linear relationship between FXIII level and platelet counts. RAHu/FXIII-A reacts with both plasma and platelet FXIII. Antiserum raised against the B subunit (RAHu/FXIII-S) reacts exclusively with native and activated FXIIIa in plasma. FXIIIa results from activation of FXIII by thrombin after the release of fibrinopeptides A from fibrinogen. Highly purified FXIII-A is used for the immunization. Freund’s complete adjuvant is used in the first step of the immunization procedure.
Specificity: Precipitating polyclonal Rabbit antiSerum to Human coagulation factor XIII-A.
UniProt: P00488
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
Background: The defined antibody reactivity is restricted to Factor XIII and FXIIIa in plasma and to platelet FXIII. As tested at the level of sensitivity of immunoprecipitation techniques a single precipitin line is obtained in bidimensional electrophoresis, immunoelectrophoresis and double radial immunodiffusion (Ouchterlony) which shows a reaction of full identity with A subunits of FXIII. No reaction is obtained with FXIII-depleted plasma and with B subunits. In precipitating techniques as electroimmunodiffusion, immunoelectrophoresis and single and double radial immunodiffusion (Mancini, Ouchterlony). To prepare an adsorbent for immunoaffinity purification of FXIII. If used in more sensitive test procedures or as catching or detection antibody in solid phase immunoassays specificity controls should always be include. Increase in plasma FXIII has been observed in type IV hyperlipoproteinaemia and in combined hyperlipodaemia. Congenital and acquired FXIII deficiencies have also been reported. In some cases of myeloma, inhibition of FXIII activity by the paraproteins may occur.
Source: Plasma FXIII is an active transglutaminase until it is activated (FXIIIa). It consists of two A subunits joined as a dimer, connected to two B subunits (A2B2). Each A subunit has a molecular weight of 75,000 and each B subunit of 80,000, making an aggregate molecular weight of the whole molecule of 320,000. Normal plasma contains about 20mg/ml. Platelet FXIII consists of only A subunits synthesized in the megakaryocytes. It accounts for about 50% of the total blood FXIII activity with a linear relationship between FXIII level and platelet counts. RAHu/FXIII-A reacts with both plasma and platelet FXIII. Antiserum raised against the B subunit (RAHu/FXIII-S) reacts exclusively with native and activated FXIIIa in plasma. FXIIIa results from activation of FXIII by thrombin after the release of fibrinopeptides A from fibrinogen. Highly purified FXIII-A is used for the immunization. Freund’s complete adjuvant is used in the first step of the immunization procedure.
Specificity: Precipitating polyclonal Rabbit antiSerum to Human coagulation factor XIII-A.
UniProt: P00488
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
| Artikelnummer | RAHu/FXIII-A |
|---|---|
| Hersteller | Nordic-MUbio |
| Hersteller Artikelnummer | RAHu/FXIII-A |
| Green Labware | Nein |
| Verpackungseinheit | 1 ml |
| Mengeneinheit | STK |
| Reaktivität | Human |
| Klonalität | Polyclonal |
| Methode | Immunoprecipitation |
| Wirt | Rabbit |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
